Junshi’s Novel SARS-CoV-2 Therapy Out-Performs Pfizer’s Paxlovid
publication date: May 25, 2022
Shanghai Junshi Biosciences reported that its novel SARS-CoV-2 therapy reduced recovery time in a Phase III trial compared to Pfizer’s Paxlovid, the current standard of care. According to Junshi, its candidate, VV116, provided a statistically significant improvement in time-to-recovery among patients with mild to moderate COVID-19 who are at high risk for disease progression. VV116 is an oral nucleoside analog drug that inhibits the replication of SARS-CoV-2. It was developed by several China government institutes including the Shanghai Institute of Materia Medica, plus Suzhou Vigonvita Life Sciences and Junshi Bio. More details....
Stock Symbols: (HK: 1877; SHA: 688180)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.